eicosapentaenoic acid (ethyl-EPA). It is a long chain highly unsaturated fatty.
In April 2009, Amarin announced that a Marketing Authorization Application (MAA) for AMR101 in patients with Huntingtons disease (HD) was accepted for review by the European Medicines Agency (EMEA). HD is a genetic neurodegenerative disease characterized by movement disorder, dementia and psychiatric disturbance. (More on Huntingtons Disease)
In progressive neurodegenerative diseases, it is thought that the functionality and effectiveness of affected neurons decline over time, and ultimately die. Neurons that are experiencing such neuronal dysfunction are often described as “suffering neurons”. The mechanism of action of AMR101 is believed to involve (1) replenishment of the lipid bi-layer potentially restoring the functions of suffering neurons, (2) reducing the over production of enzymes (PLA2) associated with apoptosis and (3) stabilizing mitochondrial integrity of suffering neurons by acting on specific signal transduction pathways and changing cellular energy metabolism. This may prevent or slow progression from neuronal dysfunction to apoptosis. Preclinical studies have shown that in aging brains, AMR101 demonstrates neuro anti-inflammatory effects, potentially protecting the brain from inflammation, which is often associated with a number of neurodegenerative diseases such as Alzheimer’s, Parkinsons and HD. Age-related learning and memory decline in the brain has also been shown to be accompanied by inflammatory changes, typified by microglial activation.
AMR101 for HD - Amarin
Shared via AddThis